Literature DB >> 21298822

Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies.

Rohan R Walvekar1,2, Pedro A Andrade Filho1, Raja R Seethala3, William E Gooding4, Dwight E Heron5, Jonas T Johnson1, Robert L Ferris1,6.   

Abstract

BACKGROUND: The aim of this study, using a retrospective chart review as the primary study design, was to determine the relative contribution of clinicopathologic risk factors versus low- and high-risk grade histologic groups to assist management of primary parotid cancers.
METHODS: In all, 168 primary parotid malignancies were treated surgically at a tertiary care center from 1982 to 2005. Of these, 115 patients with complete follow-up information were further analyzed. Pathologic updating and reclassification in 28% of cases enabled comparison of tumor histology or grade with current consensus criteria. Clinical outcomes of high- and low-risk histology and grade were compared with the influence of traditional clinicopathologic risk factors.
RESULTS: Of 115 cases, the male:female ratio was equal and the median age was 63 years (range, 15 to 89 years). Mucoepidermoid carcinoma (n = 28) was the most common histology. The median follow-up was 44 months (range, 0–278 months). Of low-risk histology patients who underwent neck dissection 40% had pN+ disease. The median time to recurrence was not reached for low-risk tumors, compared with 29 months for high-risk tumors (p = .0001). Interestingly, extracapsular spread (ECS) and margin status were independent prognostic factors and conferred significantly greater prognostic value than histologic grade risk group. Disease-free survival (DFS) and overall survival (OS) at 5 years for the entire cohort were 51% and 57%, respectively. Risk group was a strong independent predictor of OS but not DFS.
CONCLUSIONS: Risk group defined by histology and grade was associated with DFS. ECS and margin status were independent predictors of DFS. Inclusion of ECS and margin status substantially improved the prediction of disease recurrence, supporting elective neck dissection and postoperative radiotherapy for high-grade tumors or low-risk histologies with positive margins or ECS.

Entities:  

Mesh:

Year:  2011        PMID: 21298822      PMCID: PMC4164959          DOI: 10.1002/hed.21433

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  20 in total

Review 1.  Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes.

Authors:  Margaret S Brandwein; Alfio Ferlito; Patrick J Bradley; Jos J Hille; Alessandra Rinaldo
Journal:  Acta Otolaryngol       Date:  2002-10       Impact factor: 1.494

2.  Carcinoma of major salivary glands. Recent trends.

Authors:  R H Spiro; J Armstrong; L Harrison; N L Geller; S Y Lin; E W Strong
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1989-03

3.  Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985-1994 Dutch Head and Neck Oncology Cooperative Group database.

Authors:  Vincent L M Vander Poorten; Augustinus A M Hart; Bernardus F A M van der Laan; Robert J Baatenburg de Jong; Johannes J Manni; Henri A M Marres; Cees A Meeuwis; Herman Lubsen; Chris H J Terhaard; Alfonsus J M Balm
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

4.  Salivary neoplasms: overview of a 35-year experience with 2,807 patients.

Authors:  R H Spiro
Journal:  Head Neck Surg       Date:  1986 Jan-Feb

5.  Adenoid cystic carcinoma of the salivary glands: clinicopathological survey of 51 patients.

Authors:  V N Koka; R M Tiwari; I van der Waal; G B Snow; J Nauta; A B Karim; A H Tierie
Journal:  J Laryngol Otol       Date:  1989-07       Impact factor: 1.469

6.  Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients.

Authors:  Peter Wahlberg; H Anderson; A Biörklund; T Möller; R Perfekt
Journal:  Oral Oncol       Date:  2002-10       Impact factor: 5.337

7.  Carcinoma of the parotid gland.

Authors:  Peter Zbären; Jonas Schüpbach; Michel Nuyens; Edouard Stauffer; Richard Greiner; Rudolf Häusler
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

8.  High incidence of lymph node metastasis in major salivary gland cancer.

Authors:  Eberhard Stennert; Dilek Kisner; Markus Jungehuelsing; Orlando Guntinas-Lichius; Ursula Schröder; Hans Edmund Eckel; Jens Peter Klussmann
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-07

9.  Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group.

Authors:  Chris H J Terhaard; H Lubsen; I Van der Tweel; F J M Hilgers; W M H Eijkenboom; H A M Marres; R E Tjho-Heslinga; J M A de Jong; J L N Roodenburg
Journal:  Head Neck       Date:  2004-08       Impact factor: 3.147

10.  Salivary duct carcinoma.

Authors:  A Sefik Hosal; Chunyang Fan; Leon Barnes; Eugene N Myers
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more
  10 in total

1.  Occurrence of lymph node metastasis in early-stage parotid gland cancer.

Authors:  Markus Stenner; Christoph Molls; Jan C Luers; Dirk Beutner; Jens P Klussmann; Karl-Bernd Huettenbrink
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-14       Impact factor: 2.503

2.  Kaplan-Meier analysis of salivary gland tumors: prognosis and long-term survival.

Authors:  Yair Israel; Adi Rachmiel; Konstantin Gourevich; Rafael Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-11       Impact factor: 4.553

3.  A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.

Authors:  Mark R Gilbert; Arun Sharma; Nicole C Schmitt; Jonas T Johnson; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-05-01       Impact factor: 6.223

4.  Predictors of recurrence and survival for head and neck mucoepidermoid carcinoma.

Authors:  Serena A Byrd; Matthew E Spector; Thomas E Carey; Carol R Bradford; Jonathan B McHugh
Journal:  Otolaryngol Head Neck Surg       Date:  2013-05-21       Impact factor: 3.497

5.  The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.

Authors:  Glenn J Hanna; Ji Eun Bae; Jochen H Lorch; Robert I Haddad; Vickie Y Jo; Jonathan D Schoenfeld; Danielle N Margalit; Roy B Tishler; Laura A Goguen; Donald J Annino; Nicole G Chau
Journal:  Oncologist       Date:  2020-04-20

6.  Clinical features and differential diagnoses in laryngeal mucoepidermoid carcinoma.

Authors:  Sepideh Mokhtari; Saeedeh Mokhtari
Journal:  Clin Med Insights Pathol       Date:  2011-12-06

7.  Nomograms predictive for oncological outcomes in malignant parotid tumours: recurrence and mortality rates of 228 patients from a single institution.

Authors:  Giuditta Mannelli; Franchi Alessandro; Fasolati Martina; Cecconi Lorenzo; Alessandra Bettiol; Alfredo Vannacci; Gallo Oreste
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-25       Impact factor: 3.236

8.  Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines.

Authors:  S Sood; M McGurk; F Vaz
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

9.  Facial nerve reconstruction following radical parotidectomy and subtotal petrosectomy for advanced malignant parotid neoplasms.

Authors:  Rocío Sánchez-Burgos; Teresa Gonzalez Otero; Luis Lassaletta; Javier Arias Gallo; Ignacio Navarro Cuellar; Miguel Burgueño García
Journal:  Ann Maxillofac Surg       Date:  2015 Jul-Dec

10.  Bulbar conjunctival metastasis from mucoepidermoid carcinoma of parotid-a case report and review of literature.

Authors:  Rajshri Yadav; Azhar J Battoo; Abdul W Mir; Altaf G Haji
Journal:  World J Surg Oncol       Date:  2017-01-07       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.